Abdera Therapeutics emerged from stealth with technology that improves the way antibodies deliver radiopharmaceuticals for cancer. A lead program with preclinical proof-of-concept data in small cell lung cancer is on track to reach the clinic in 2024.
NorthStar’s Mo-99 program continues at the forefront of U.S. radioisotope production as the only commercialized producer of key medical radioisotopes molybdenum-99 (Mo-99)/technetium-99m (Tc-99m
/PRNewswire/ BioSpace, the leading life sciences news and careers site, has announced its 2023 selections for the industry s most promising up-and-coming.
Curie Therapeutics will be provided with priority access to NorthStar’s high purity non-carrier added (n.c.a.) Ac-225, which will be used to advance its multimodal pipeline of precision radiopharmaceuticals to address broad unmet needs in treatment of patients with solid tumors
Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that members of management will present at the Guggenheim